钠-葡萄糖共转运蛋白2抑制剂治疗非糖尿病疾病的系统综述
Systematic Review of Sodium-glucose Cotransporter 2 Inhibitors in the Treatment of Non-diabetic Diseases
韦海燕 1郭予洁1
作者信息
- 1. 柳州市人民医院老年病科,广西 柳州 545000
- 折叠
摘要
钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂作为一种新型降糖药,为糖尿病患者带来新的获益.近年来研究发现,SGLT-2抑制剂在心血管疾病、肾脏病、减重、非酒精性脂肪性肝病等非糖尿病疾病中有显著的治疗作用.现就SGLT-2抑制剂在非糖尿病疾病中的作用机制、安全性及临床应用要点等方面的研究做一综述,为SGLT-2抑制剂在非糖尿病疾病的治疗提供更多的临床应用依据.
Abstract
Sodium-glucose cotransporter 2(SGLT-2)inhibitor,as a new type of hypoglycemic agent,brings new benefits to diabetic patients.Recent studies have found that SGLT-2 inhibitors have significant therapeutic effects on non-diabetic diseases such as cardiovascular disease,kidney disease,weight loss,and non-alcoholic fatty liver disease.Here is to make a review on the mechanism,safety and clinical application of SGLT-2 inhibitors in non-diabetic diseases,so as to provide more clinical application basis for SGLT-2 inhibitors in the treatment of non-diabetic diseases.
关键词
SGLT-2抑制剂/非糖尿病疾病/心血管疾病/肾脏病/减重/非酒精性脂肪性肝病Key words
SGLT-2 inhibitors/Non-diabetic disease/Cardiovascular disease/Kidney disease/Lose weight/Non-alcoholic fatty liver disease引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据